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Introduction
According to the latest annual report by the Japanese 
Association for Thoracic Surgery, approximately 64,000 
cardiovascular surgeries (CVSs) and 36,000 surgeries for 
primary lung cancer are performed annually in Japan [1]. 
While recent long-term results following CVS have been 
favorable and general thoracic surgeons often perform lung 
cancer surgery after CVS, previous CVS is associated with 
problems during lung cancer surgery. First, some patients 
on antithrombotic therapy need to have their drugs sus-
pended temporarily and be commenced on bridging antico-
agulation therapy, indicating that they are at risk of bleed-
ing and thrombosis. Second, adhesion in the pleural cavity 
from the previous CVS may result in severe intraoperative 
complications including bypass graft injury. Third, the risk 
of perioperative cardiovascular events in these patients 
remains unclear. In the present study, we used a thoracic 
revised cardiac risk index (ThRCRI), proposed by Brunelli 
et al. and Ferguson et al. [2–6], as a risk assessment tool 
for major cardiovascular events in the perioperative period. 
As there is no clear mechanism of how previous CVS 
affects the long-term results of non-small cell lung cancer 
(NSCLC) surgery, we investigated the surgical outcomes 
and long-term results of NSCLC resection in patients with 
a history of CVS.
Patients and methods
Patient groups
This retrospective study was based on the medical records 
at a single institute. We reviewed the clinical data of 
patients who underwent lung resection for NSCLC at 
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our institute between January, 2003 and December, 2014 
(n = 1138). Patients who underwent lung resection were 
divided into three groups: Those who had a history of 
CVS were classified as the study group (SG); those who 
did not have a history of CVS were classified as the con-
trol group (CG); and those with cardiovascular diseases but 
no history of CVS were classified as the specified control 
group (SCG). Cardiovascular diseases in the SCG included 
coronary artery disease (n = 93), valvular disease (n = 9), 
aortic aneurysm (n = 13), cardiomyopathy (n = 11), and 
arrhythmia (n = 42). Coronary artery disease (CAD) was 
treated with percutaneous coronary intervention (PCI) or 
medication, and the other diseases were controlled with 
medication. This study compared the surgical outcomes of 
the SG with those of the CG and SCG. The postoperative 
observation period was defined as the period from the oper-
ation to the last follow-up appointment.
Preoperative evaluation of cardiac function
Preoperative resting electrocardiogram (ECG) and ultra-
sound echocardiography (UCG) were performed in all 
patients. Brain natriuretic peptide (BNP) was measured 
according to advice by the surgeon. Coronary angiography 
(CAG) was performed in patients with a history of a coro-
nary artery bypass graft (CABG) or CAD, if recommended 
by cardiologists.
Management of antithrombotic agents
The discontinuation of antithrombotic agents or the ini-
tiation of bridging therapy was decided by cardiologists. 
Antiplatelet agents were ceased 7 days before surgery, with 
warfarin discontinued 5–7 days before surgery and replaced 
by therapeutic bridging with unfractionated heparin (UFH). 
UFH was continued until 4–6 h before surgery and resumed 
as soon as possible after confirming no postoperative bleed-
ing. The oral agents were resumed after postoperative day 
1, and UFH was continued until the blood concentration or 
prothrombin time-international ratio was within the thera-
peutic range.
Risk assessment for a postoperative major cardiac 
event
This study used ThRCRI to assess the risk of a periopera-
tive major cardiovascular event. Postoperative major car-
diovascular complications were defined as those occurring 
during admission or within 30 days after surgery. They 
included myocardial infarction (MI), pulmonary edema, 
ventricular arrhythmia requiring intervention or primary 
cardiac arrest, complete heart block, or any cardiac-related 
death [3, 4]. ThRCRI is a four-class risk score that includes 
four weighed factors: ischemic heart disease (IHD), defined 
as a history of MI, a positive exercise test, current com-
plaint of chest pain considered to be related to myocardial 
ischemia, use of nitrate therapy, or an electrocardiogram 
with pathologic Q waves (score 1.5 points); cerebrovascu-
lar disease history, defined as a transient ischemic attack or 
stroke (score 1.5 points); a serum creatinine level of greater 
than 2 mg/dL (score 1 point); and pneumonectomy (score 
1.5 points) [6]. The four ThRCRI classes based on the 
scores were as follows: category A (0 points), category B 
(1–1.5 points), category C (2–2.5 points), and category D 
(>2.5 points) [4]. The risk of a major cardiovascular event 
increases from class A to D [2–5]. In scoring the factors (1), 
if patients who underwent CABG for IHD were not tak-
ing any medication, they hardly obtained 1.5 points. This 
study further compared the risk in patients who underwent 
a major lung resection (lobectomy, bilobectomy, and pneu-
monectomy) between the two sets of two groups; namely, 
SG vs. CG and SG vs. SCG.
Operative approaches
The surgical approach was classified into three categories: 
complete video-assisted thoracoscopic surgery (VATS), 
hybrid VATS (hVATS), and open thoracotomy (OT). Com-
plete VATS was performed through a three- or two-port 
with utility minithoracotomy under thoracoscopic view. 
hVATS was performed through a two-port with anterolat-
eral minithoracotomy under thoracoscopic view and direct 
visualization.
Lung cancer staging
Lung cancer staging was done in accordance with the sev-
enth edition of the tumor node metastasis (TNM) classifi-
cation of lung cancer, as proposed by the Union for Inter-
national Cancer Control and the International Association 
for the Study of Lung Cancer, 2009. For those patients who 
underwent lung resection before 2009, staging was still 
matched to the criteria in the seventh edition of the TNM 
classification.
Definition of a perioperative event
Intraoperative bleeding was defined as requiring a blood 
transfusion or conversion to hVATS or OT to control the 
bleeding. Complications that occurred within 30 days of 
surgery were considered as postoperative complications 
and included arrhythmia that required intervention, pro-
longed air leakage that required pleurodesis, or bleeding 
that required a blood transfusion or reoperation. We defined 
30- and 90-day mortality as death within 30 and 90 days 
after surgery, including after discharge, respectively.
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Statistical analyses
Continuous data are presented as the median and the inter-
quartile range (IQR), and categorical data are presented 
as numbers and percentages. For comparing two groups, 
continuous data were analyzed by the Mann–Whitney’s U 
test, and categorical data were analyzed by the Fischer’s 
exact test or Chi-square test. A forward stepwise multiple 
regression analysis was performed to elucidate the rela-
tionships among intraoperative blood loss as a dependent 
variable and the following factors as independent variables: 
the presence of adhesion caused by previous CVS, bridg-
ing therapy, operation time, operative approach, and opera-
tive method. Logarithmic transformation of the depend-
ent variable was performed to normalize its distribution. 
The 5-year survival rate of patients between January, 2003 
and December, 2013 was estimated by the Kaplan–Meier 
method and differences between the two sets of the two 
groups were analyzed by the log-rank test. Probability less 
than 0.05 (p < 0.05) was considered significant. All statisti-
cal analyses were performed with JMP Pro 12.1 statistical 
software (SAS Institute, Cary, NC, USA).
Ethics
This study was approved by the Research Ethics Com-
mittee of the Tokyo Women’s Medical University, Tokyo, 
Japan (No. 3568).
Results
During the study period, 36 patients with a history of CVS 
underwent lung resection for NSCLC at our hospital. Of 
these 36 patients, 30 (83.3 %) received antithrombotic ther-
apy, 19 (52.8 %) of whom also required bridging therapy 
in the perioperative period. According to preoperative rest-
ing UCG, the median ejection fraction was 55.2 % (IQR 
50–65.6 %), and the median fractional shortening was 
29.5 % (IQR 25.5–37 %). None of the patients underwent 
stress echocardiography. Preoperative BNP was measured 
in 17 patients, and the median level of BNP was 98.2 pg/
mL (IQR 64.6–181.3 pg/mL). CAG was performed in 11 
patients with a CABG history. A new diagnosis of CD was 
made in five patients, and PCI was performed for graft 
stenosis in seven patients. The median duration between 
previous CVS and lung resection was 96 months (IQR 
49–152 months). The median postoperative observation 
period was 34.5 months (IQR 12.5–63.3 months).
Table 1 summarizes the baseline characteristics of 
the patients. There were significant differences in age 
(p = 0.0283), gender (p = 0.0081), number of comorbidi-
ties (p = 0.0066), and number of patients who required 
bridging therapy (p < 0.0001) between the SG and CG; 
and the number of comorbidities between the SG and SCG 
(p < 0.0001). The ThRCRI class was significantly differ-
ent between the SG and SCG (p < 0.0001). The most com-
mon ThRCRI classes were class A in the SG and CG, and 
class B in the SCG. Table 2 shows the different CVS proce-
dures that the SG patients underwent. CABG was the most 
common procedure, followed by aortic valve replacement. 
Combined surgical procedures included CABG with Dor, 
and CABG with mitral valve replacement. Surgery for con-
genital heart disease included ventricular septal defect clo-
sure with aortic valve replacement and atrial septal defect 
(ASD) closure. Eight patients had adhesion in the pleural 
cavity from the previous CVS (Table 3). Graft replacement 
and ASD closure were performed via lateral thoracotomy, 
and the other procedures were performed via median ster-
notomy. All of the patients with CABG history had adhe-
sions surrounding the internal thoracic artery (ITA) grafts. 
There were no injuries to the ITA grafts caused by the dis-
section of adhesions.
There were no significant differences between the 
two sets of two groups in surgical and clinical outcomes 
(Table 4). In the SG, 24 patients underwent a major 
resection, 12 underwent a sublobar resection, and none 
underwent pneumonectomy. Three intraoperative com-
plications occurred in the SG. In two patients, bleeding 
from pulmonary artery necessitated the VATS proce-
dure to be converted to thoracotomy. In one patient, the 
blood pressure dropped after the induction of anesthesia, 
but the cause of this could not be determined, as ECG 
showed no evidence of IHD or arrhythmia. The operative 
method was then converted from lobectomy to wedge 
resection to shorten the operative time and no other intra-
operative event occurred. Table 5 outlines the postopera-
tive complications in both groups. In the SG, postopera-
tive arrhythmia (atrial flutter), bleeding, and chylothorax 
did not require reoperation and there was no incidence 
of thrombosis, ventricular arrhythmia, or acute coronary 
syndrome in this group. Cardiovascular complications 
occurred at incidences of 2.8 % (n = 1) in the SG and 
4.1 % (n = 6) in the SCG. One patient from the CG and 
SCG suffered a major cardiovascular event related to 
ventricular tachycardia. The 30- and 90-day mortality 
rate in the SG was zero.
Forward stepwise multiple regression analysis 
showed that the operative time (standardized β = 0.641, 
p < 0.0001), hVATS, or OT (standardized β = 0.294, 
p = 0.0272) were correlated with the intraoperative blood 
loss. Adhesion caused by previous CVS and bridging ther-
apy was uncorrelated with the intraoperative blood loss.
The 5-year overall survivals rates of patients with 
all stages vs. stage I were 69.3 and 83.5 % in the SG, 
73.9 and 82.2 % in the CG, and 65.4 and 70.4 % in the 
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SCG, respectively (Fig. 1). There were no significant dif-
ferences between the two sets in two groups (all stages: 
p = 0.97, p = 0.521, stage I: p = 0.686, p = 0.237). In 
the SG, there were seven late deaths during the observa-
tion period; caused by lung cancer in six and CHF in one. 
The pathological staging results for the patients who died 
of lung cancer were stage IA (n = 2), IIB (n = 2), and IIIA 
(n = 2). Two patients with stage IA disease underwent lim-
ited resection because of poor cardiac function.
Discussion
In this series of patients who underwent surgery for 
NSCLC, none of those with a history of CVS (SG) suf-
fered severe cardiovascular complications in the periopera-
tive period and their postoperative results were favorable, 
in spite of significant differences in age and the number 
of preoperative comorbidities from those of the control 
group (CG). On the other hand, those without a history of 
CVS, but with coexisting cardiac disease (SCG) had the 
highest incidence of postoperative cardiovascular com-
plications. Although 52.8 % of the SG patients required 
bridging anticoagulant therapy, there were no significant 
differences in the duration of drainage or length of hospi-
tal stay from those of the CG. A forward stepwise multiple 
Table 1  Comparison of patient characteristics
ThRCRI thoracic revised cardiac risk index
* Based on Fischer’s exact test or Chi-square test (categorical variables), or Mann–Whitney’s U test (continuous variables). Continuous variables 
are expressed as median and interquartile range; categorical variables are expressed as a number and percentage
Variables Study group (SG) Control group (CG) Specified control group (SCG) p value*
SG vs. CG SG vs. SCG
Total number of patients 36 1102 147
Age (years) 73 (66.8–77.3) 69 (62–75) 74 (68–78) 0.0283 0.55
Gender 0.0081 0.372
 Male 31 (86.1) 714 (64.8) 117 (79.6)
 Female 5 (13.9) 388 (35.2) 30 (20.4)
Clinical stage 0.514 0.803
 I 31 (86.1) 801 (72.7) 114 (77.5)
 II 2 (5.6) 120 (10.9) 14 (9.5)
 III 3 (8.3) 150 (14.1) 17 (11.6)
 IV 0 26 (2.3) 2 (1.4)
Number of comorbidity 0.0066 <0.0001
 0 5 (13.9) 354 (32.1) 5 (3.4)
 1 22 (61.0) 359 (32.6) 25 (17)
 2 5 (13.9) 246 (22.3) 51 (34.7)
 3 2 (5.6) 104 (9.4) 45 (30.6)
 ≥4 2 (5.6) 39 (3.6) 21 (14.3)
ThRCRI class 0.632 <0.0001
 A 22 (91.7) 526 (82.2) 25 (29.4)
 B 2 (8.3) 101 (15.8) 50 (58.8)
 C 0 5 (0.8) 7 (8.3)
 D 0 8 (1.2) 3 (3.5)
Bridging therapy <0.0001 0.584
 + 19 (52.8) 158 (14.3) 62 (42.2)
 – 17 (47.2) 944 (85.7) 85 (57.8)
Table 2  Types of previous cardiovascular surgery
CABG coronary artery bypass grafting, TAR total arch replacement
Operative method n = 36
CABG 21
Valve replacement 6
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Table 3  Cases of adhesion due to previous cardiovascular surgery
ASD indicates atrial septum defect, AVR aortic valve replacement, CABG coronary artery bypass graft, ITA internal thoracic artery, LITA left 
internal thoracic artery, LLL left lower lobectomy, LUL left upper lobectomy, RITA right internal thoracic artery, RLL right lower lobectomy, 
RML right middle lobectomy, RUL right upper lobectomy, TAA thoracic aorta aneurysm
Previous cardiovascular surgery Locations of adhesion Types of lung resection Number of cases (n = 8)
CABG Surroundings of ITA graft 5
 RITA RUL 3
RML 1
 LITA LUL 1
Graft replacement for TAA In front of left upper lobe Left S6 segmentectomy 1
AVR Total pleural adhesion LLL 1
ASD closure Total plural adhesion RLL 1
Table 4  Comparison of surgical and clinical outcomes
VATS video-assisted thoracoscopic surgery
* Based on Fischer’s exact test or Chi-square test (categorical variables), or Mann–Whitney’s U test (continuous variables). Continuous variables 
are expressed as median and interquartile range; categorical variables are expressed as a number and percentage
Variables Study group (SG) (n = 36) Control group (CG) 
(n = 1102)
Specified control group  
(SCG) (n = 147)
p value*
SG vs. CG SG vs. SCG
Operative approach 0.172 0.375
 Complete VATS 28 (77.8) 839 (76.1) 108 (73.5)
 Hybrid VATS 4 (11.1) 56 (5.1) 10 (6.8)
 Open thoracotomy 4 (11.1) 207 (18.8) 29 (19.7)
Operative method 0.834 0.355
 Wedge resection 6 (16.7) 171 (15.7) 33 (19.7)
 Segmentectomy 6 (16.7) 239 (21.9) 29 (22.5)
 Lobectomy 23 (65.3) 627 (57.6) 82 (55.8)
 Bilobectomy 1 (2.8) 29 (2.7) 3 (2)
 Pneumonectomy 0 23 (2.1) 0
Operative time (min) 204 (152–280) 195 (145–248) 191 (133–257) 0.334 0.304
Blood loss (ml) 102.5 (10–323) 74 (15–213) 70 (10–419) 0.528 0.357
Intraoperative complication 3 (8.3) 42 (3.8) 3 (2) 0.171 0.246
 Bleeding 2 39 2
 Others 1 3 1
Duration of drainage (days) 4 (3–6) 3 (3-5) 4 (3–6) 0.220 0.725
Length of stay (days) 10 (8–12) 10 (7–13) 11 (8–14) 0.804 0.725
Postoperative complication 4 (11.1) 116 (10.5) 21 (14.3) 0.911 0.619
30-day mortality 0 6 (0.54) 3 (2) 1 1
90-day mortality 0 7 (0.64) 4 (2.2) 1 1
Pathology 0.300 0.82
 Adenocarcinoma 23 (63.9) 822 (74.6) 98 (66.7)
 Squamous cell carcinoma 10 (27.8) 198 (18.0) 15 (10.2)
 Others 3 (8.3) 82 (7.4) 34 (23.1)
Pathological stage 0.870 0.831
 I 28 (77.8) 767 (69.6) 109 (74.2)
 II 3 (8.3) 138 (12.5) 19 (12.9)
 III 5 (13.9) 172 (15.6) 17 (11.5)
 IV 0 25 (2.3) 2 (1.4)
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Table 5  Details of 
postoperative complications in 
both groups
CHF congestive heart failure, IP interstitial pneumonia
Study group Control group Specified control group
Total number of complications 5 135 28
Cardiovascular
Arrhythmia 1 8 5
CHF 0 3 1
Bleeding 1 5 1
Acute exacerbation of IP 1 14 2
Prolonged air leakage 1 50 7
Chylothorax 1 3 3
Others 0 52 9
Fig. 1  The survival curves of all stages and stage I of the two sets of 
two groups, which were the study group (SG) vs. the control group 
(CG), SG vs. the specified control group (SCG). a The 5-year sur-
vival rates of patients with all stages of lung cancer; 69.3 % in SG 
(red line, n = 31) and 73.9 % in CG (blue line, n = 994). b The 
5-year survival rates of patients with stage I lung cancer; 83.5 % in 
SG (red line, n = 23) and 82.2 % in CG (blue line, n = 682). c The 
5-year survival rates of patients with all stages of lung cancer; 69.3 % 
in SG (red line, n = 31) and 65.4 % in SCG (blue line, n = 135). d 
The 5-year survival rates of patients with stage I lung cancer; 83.5 % 
in SG (red line, n = 23) and 70.4 % in SCG (blue line, n = 102)
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regression analysis showed that the bridging therapy and 
adhesion from previous CVS hardly influenced the intraop-
erative blood loss. Some guidelines on the management of 
antithrombotic agents in the perioperative period have been 
reported in Japan and Western countries [7–10]. While 
low-molecular weight heparin (LMWH) is generally used 
for bridging therapy in Western countries [7–9], UFH is 
used in Japan, because LMWH for bridging therapy is not 
covered by insurance. Although there are few differences 
in the time of resuming the agents after surgery, guide-
lines recommend that LMWH or UFH should be resumed 
after confirming no postoperative bleeding. This study also 
showed no significant thrombosis when adequate bridging 
therapy was given, even though these patients have a poten-
tial risk of thrombosis in the perioperative period. Fur-
thermore, as postoperative atrial fibrillation (af), the most 
common arrhythmia after lung resection, can cause severe 
thrombosis, with sequela such as cerebral infarction, it is 
important to predict its occurrence in patients with previous 
CVS. Iwata et al. [11] reported that BNP and early trans-
mitral velocity/tissue Doppler mitral annular early diastolic 
velocity in UCG findings may be risk factors for postop-
erative af. These preoperative examinations are commonly 
performed for patients with a history of CVS and may be 
useful predictors of postoperative af. Yamamoto et al. [12] 
also reported a high incidence of cerebral infarction in 
patients who undergo left upper lobectomy for lung cancer. 
However, the incidence of postoperative cerebral infarction 
after left upper lobectomy in patients with a history of CVS 
remains unclear and needs further investigation.
When thoracic surgeons perform lung resection in patients 
with a history of CVS, adhesions from their previous sur-
gery can often make the resection more difficult. Adhesion 
between the ITA and the lung after CABG with an ITA graft 
must be dissected very carefully. To prevent graft injury, a 
technique was devised to leave the lung parenchyma on the 
graft, using a stapler [13, 14]. We applied this technique in 
two of the patients in this series, as we were concerned that 
their remnant lung parenchyma might become a source of 
infection. Shah et al. [13] reported that the incidence of pyo-
thorax was higher in patients who underwent this technique 
than in a control group; however, there was no difference in 
cancer recurrence rates between two groups. If a graft injury 
can lead to fatal complications, this technique should be con-
sidered. In this study, patients who had undergone previous 
surgery via thoracotomy, including graft replacement for 
TAA or ASD closure, had extensive adhesions in the pleural 
cavity. VATS was very useful for providing good visualiza-
tion to allow us to dissect the adhesions. In preparation for 
surgery, past operation records should be studied thoroughly 
to facilitate a safe surgical procedure.
According to an analysis of lung cancer registry cases in 
Japan, the rates of postoperative cardiovascular complications 
were 0.47 % for CHF, 0.07 % for MI, and 3.3 % for arrhyth-
mia [15]. Thus, severe cardiovascular events rarely occur 
because of the progression of perioperative management and 
fortunately this study had no life-threatening events. Previous 
reports document the surgical results of patients undergoing 
lung cancer surgery with cardiovascular comorbidities [16–
19]. Takenaka et al. [16] reported no increases in the post-
operative morbidity and mortality rates and no influence on 
the long-term results, while Senbaklavaci et al. [20] reported 
that a CVS history hardly increased morbidity and mortality 
after major lung resection. In contrast, Ambrogi et al. [17] 
reported an increase in postoperative morbidity with a worse 
prognosis. Most thoracic surgeons will be concerned about 
the possibility of perioperative cardiovascular events in these 
patients. Brunelli et al. [2] proposed ThRCRI as a recalibrated 
version of the revised cardiac index. External validation in a 
single institute is verified [3, 4]: Ferguson et al. [5] reported 
the utility of a risk assessment of major postoperative cardio-
vascular events, referring to related cases from the Society of 
Thoracic Surgeons database. Brunelli et al. [6] reported that 
ThRCRI can be used to stratify the long-term prognosis after 
curative resection for stage I lung cancer. In our study, there 
was no significant difference in ThRCRI between the SG and 
the CG; however, when a risk assessment was done based on 
the ThRCRI, it was generally considered that patients with a 
history of CVS might be at higher risk of perioperative car-
diovascular events because CAD and an aortic aneurysm are 
known to frequently coexist [21, 22]. CHF can develop in the 
long term in patients with a CVS history, and cardiovascular 
disease often develops in patients with systemic arteriosclero-
sis, diabetes mellitus, and chronic renal failure on hemodialy-
sis. These are all risk factors for cerebrovascular disease and 
renal insufficiency and the four ThRCRI categories develop 
frequently in these patients. On the other hand, the most 
common ThRCRI class in the SCG in the present study was 
class B and there was a significant difference in the class of 
ThRCRI between the SG and the SCG because some patients 
who had undergone CABG for IHD were free from medica-
tions, they had no score factor, and 93 patients in the SCG 
had CAD, indicating that a higher ThRCRI score and another 
ThRCRI category were not uncommon in the SCG.
To maximize the chances of safe lung resection in 
patients with a history of CVS, their current cardiac condi-
tion must be assessed prior to performing the lung surgery. 
Therefore, we should expect that future lung resection after 
revascularization by CABG can be performed safely. Ser-
geant et al. reported that the percentages of patients who 
did not undergo any reintervention within 10 and 15 years 
after CABG were 89 and 72 %, respectively [23]. By sev-
eral years post-CABG, the necessity for re-CABG and PCI 
may increase as a result of stenosis of the bypass graft and 
new CAD. This could apply to other types of CVS; for 
example, prosthetic valve dysfunction in the long term after 
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valve surgery may result in heart failure and the need for 
reoperation, resulting in worsening cardiac function.
To our knowledge, there are no reports of long-term results 
following surgery for NSCLC in patients with a history of 
CVS. In Japan, the 5-year survival rate following resection of 
lung cancer is 70 % overall: 87 % for stage IA disease and 
74 % for stage IB disease [24]. These results are consistent 
with those in the present study. The 5-year overall survival 
rate in the SG was not significantly different from those in the 
CG and the SCG. Although SG had a higher 5-year survival 
rate than the SCG for no clear reason, we speculate that the 
difference might have been affected by comorbidities other 
than lung cancer, because the number of comorbidities in the 
SCG was significantly higher than that in the SG. Although 
this study investigated a small number of cardiovascular 
events in a sample size of 36 patients, we found that previous 
CVS hardly affected the prognosis of the patients undergoing 
lung cancer resection. However, if patients undergo limited 
resection because of current poor cardiac function or severe 
adhesion, previous CVS may affect the NSCLC prognosis.
This study had some important limitations: First, it was 
a retrospective and single-institutional study and second, 
the SG had a smaller number of patients than the CG. Since 
only one patient suffered a major cardiovascular event 
appeared, a future study should be done on a greater num-
ber of patients. Third, no external validation of ThRCRI in 
Japanese patients has been performed. The types of previ-
ous CVS were heterogeneous, and an investigation of each 
type of past surgery should be considered in the future. 
Finally, cardiovascular diseases in the SCG were unable to 
be completely matched to cardiovascular diseases treated 
with surgery in the SG.
In conclusion, the adequate management of antithrom-
botic agents in the perioperative period allowed lung cancer 
resection to be performed without significant bleeding or 
thrombosis in patients with a history of CVS. This study 
showed that a history of CVS hardly increased the risk of 
a perioperative cardiovascular event and did not affect the 
prognosis of patients undergoing resection of NSCLC. 
However, limited resection due to the current cardiac sta-
tus and the extent of adhesions may affect the prognosis of 
patients undergoing resection of NSCLC.
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